Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-013239
Filing Date
2024-10-10
Accepted
2024-10-10 16:15:41
Documents
38
Period of Report
2024-08-31

Document Format Files

Seq Description Document Type Size
1 10-Q bzyr-20240831x10q.htm   iXBRL 10-Q 612165
2 EX-31.1 bzyr-20240831xex31d1.htm EX-31.1 11832
3 EX-31.2 bzyr-20240831xex31d2.htm EX-31.2 11952
4 EX-32.1 bzyr-20240831xex32d1.htm EX-32.1 6693
5 EX-32.2 bzyr-20240831xex32d2.htm EX-32.2 7123
  Complete submission text file 0001558370-24-013239.txt   2165708

Data Files

Seq Description Document Type Size
6 EX-101.SCH bzyr-20240831.xsd EX-101.SCH 17082
7 EX-101.CAL bzyr-20240831_cal.xml EX-101.CAL 17615
8 EX-101.DEF bzyr-20240831_def.xml EX-101.DEF 43967
9 EX-101.LAB bzyr-20240831_lab.xml EX-101.LAB 138071
10 EX-101.PRE bzyr-20240831_pre.xml EX-101.PRE 91220
41 EXTRACTED XBRL INSTANCE DOCUMENT bzyr-20240831x10q_htm.xml XML 192398
Mailing Address 9432 KATY FREEWAY HOUSTON TX 77055
Business Address 12000 RICHMOND AVE HOUSTON TX 77082 (713) 335-5697
BURZYNSKI RESEARCH INSTITUTE INC (Filer) CIK: 0000724445 (see all company filings)

EIN.: 760136810 | State of Incorp.: DE | Fiscal Year End: 0229
Type: 10-Q | Act: 34 | File No.: 000-23425 | Film No.: 241365398
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)